BofA raised the firm’s price target on Insmed (INSM) to $187 from $142 and keeps a Buy rating on the shares. After updating the firm’s model to include a 2030 launch of Insmed’s pro-drug TPIP and “modestly raising” its Brinsupri forecasts, BofA now forecasts 2030 adjusted total revenues of $7.8B, versus the Visible Alpha consensus of $6.0B, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Promising Market Prospects and Strong Support Drive Buy Rating for Insmed
- Positive Outlook for Insmed: Promising Product Pipeline and Favorable Market Position Justify Buy Rating
- Optimistic Buy Rating for Insmed’s Brinsupri Amid Strong Market Potential and Expansion Opportunities
- Insmed says CHMP recommends EU approval of BRINSUPRI
- Insmed price target raised to $194 from $140 at UBS